International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial.

Medical Research Council Clinical Trials Unit, London, United Kingdom.
Journal of Clinical Oncology (Impact Factor: 17.88). 06/2011; 29(16):2171-7. DOI: 10.1200/JCO.2010.32.3139
Source: PubMed

ABSTRACT This article presents the long-term results of the international multicenter randomized trial that investigated the use of neoadjuvant cisplatin, methotrexate, and vinblastine (CMV) chemotherapy in patients with muscle-invasive urothelial cancer of the bladder treated by cystectomy and/or radiotherapy. Nine hundred seventy-six patients were recruited between 1989 and 1995, and median follow-up is now 8.0 years.
This was a randomized phase III trial of either no neoadjuvant chemotherapy or three cycles of CMV.
The previously reported possible survival advantage of CMV is now statistically significant at the 5% level. Results show a statistically significant 16% reduction in the risk of death (hazard ratio, 0.84; 95% CI, 0.72 to 0.99; P = .037, corresponding to an increase in 10-year survival from 30% to 36%) after CMV.
We conclude that CMV chemotherapy improves outcome as first-line adjunctive treatment for invasive bladder cancer. Two large randomized trials (by the Medical Research Council/European Organisation for Research and Treatment of Cancer and Southwest Oncology Group) have confirmed a statistically significant and clinically relevant survival benefit, and neoadjuvant chemotherapy followed by definitive local therapy should be viewed as state of the art, as compared with cystectomy or radiotherapy alone, for deeply invasive bladder cancer.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Rund 16.000 Menschen erkranken derzeit pro Jahr in Deutschland an einem invasiven Harnblasenkarzinom. Trotz adäquat durchgeführter radikaler Zystektomie und regionaler Lymphadenektomie rezidivieren mehr als 50% der Patienten mit den lokal fortgeschrittenen Tumorstadien T2–T4a, auch wenn zunächst kein Lymphknotenbefall oder Fernmetastasen nachweisbar sind. Der Einsatz multimodaler Therapiekonzepte in Form einer neoadjuvanten oder adjuvanten Chemotherapie ist daher naheliegend. Obwohl zumindest der Nutzen einer neoadjuvanten Chemotherapie mit einer Verbesserung der Überlebensrate von rund 5–6% durch klinische Studien und Metaanalysen klar belegt ist, findet das Verfahren in Europa noch immer nur eine geringe Akzeptanz. Im Folgenden sollen die Argumente für und wider eine perioperative Chemotherapie dargestellt werden. Abstract Every year approximately 16,000 patients are diagnosed with invasive bladder cancer in Germany. Despite upfront radical cystectomy and pelvic lymphadenectomy more than 50% of patients with locally advanced clinical stages T2-T4a will suffer a relapse and eventually die from the disease even in the absence of lymph node involvement or distant metastases at the time of initial diagnosis. Consequently the addition of perioperative neoadjuvant and adjuvant chemotherapy was explored in bladder cancer with positive results in favour of neoadjuvant chemotherapy. However, despite high-level evidence from several randomized trials and meta-analyses of an improved overall survival of 5–6 % after 5 years, neoadjuvant chemotherapy is currently still underused in Europe. In this review the arguments for and against perioperative chemotherapy will be discussed.
    Der Onkologe 11/2012; 18(11):994-1002. DOI:10.1007/s00761-012-2324-9 · 0.13 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: PurposeTo apply k-means clustering of two pharmacokinetic parameters derived from 3T dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to predict the chemotherapeutic response in bladder cancer at the mid-cycle timepoint.Materials and Methods With the predetermined number of three clusters, k-means clustering was performed on nondimensionalized Amp and kep estimates of each bladder tumor. Three cluster volume fractions (VFs) were calculated for each tumor at baseline and mid-cycle. The changes of three cluster VFs from baseline to mid-cycle were correlated with the tumor's chemotherapeutic response. Receiver-operating-characteristics curve analysis was used to evaluate the performance of each cluster VF change as a biomarker of chemotherapeutic response in bladder cancer.ResultsThe k-means clustering partitioned each bladder tumor into cluster 1 (low kep and low Amp), cluster 2 (low kep and high Amp), cluster 3 (high kep and low Amp). The changes of all three cluster VFs were found to be associated with bladder tumor response to chemotherapy. The VF change of cluster 2 presented with the highest area-under-the-curve value (0.96) and the highest sensitivity/specificity/accuracy (96%/100%/97%) with a selected cutoff value.Conclusion The k-means clustering of the two DCE-MRI pharmacokinetic parameters can characterize the complex microcirculatory changes within a bladder tumor to enable early prediction of the tumor's chemotherapeutic response. J. Magn. Reson. Imaging 2015;41:1374-1382. © 2014 Wiley Periodicals, Inc.
    Journal of Magnetic Resonance Imaging 06/2014; 41(5). DOI:10.1002/jmri.24663 · 2.79 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Outcomes with cisplatin-based first-line therapy for advanced UC following prior perioperative cisplatin-based chemotherapy are unclear. This study evaluates outcomes with a focus on the impact of time from prior cisplatin-based perioperative chemotherapy (TFPC). Patients and methods Data were collected for patients who received cisplatin-based first-line therapy for advanced UC following previous perioperative cisplatin-based therapy. Cox proportional hazards models were used to investigate the prognostic ability of visceral metastasis, ECOG performance status (PS), TFPC, anemia, leukocytosis and albumin on overall survival (OS). Results Data were available for 41 patients from 8 institutions including 31 men (75.6%). The median age was 61 years (range 41 to 77), the majority received gemcitabine plus cisplatin (N=26, 63.4%) and the median number of cycles was 4 (range 1-8). The median OS was 68 weeks (95% CI: 48.0-81.0). Multivariable Cox regression analysis results showed an independent prognostic impact on OS for PS >0 vs. 0 (HR 4.56 [1.66-12.52], p=0.003) and TFPC ≥78 weeks vs. <78 weeks (HR 0.48 [0.21-1.07], p=0.072). The prognostic model for OS was internally validated with c-index=0.68. Patients with TFPC <52 weeks, 52-104 weeks and ≥104 weeks had median survival of 42, 70 and 162 weeks respectively. Conclusions Longer TFPC ≥78 weeks and ECOG-PS=0 were independently prognostic for better survival with cisplatin-based first-line chemotherapy for advanced UC following prior perioperative cisplatin-based chemotherapy. The data support employing TFPC ≥52 weeks to re-challenge with cisplatin-based first-line chemotherapy for metastatic disease.
    Clinical Genitourinary Cancer 09/2014; 13(2). DOI:10.1016/j.clgc.2014.08.010 · 1.69 Impact Factor


Available from